EQS-Adhoc: FamiCord AG acquires majority stake in Národní Centrum Pupečníkové Krve and Rodinná banka perinatálnych a mezenchymálnych buniek

Leipzig, 28 May 2025 – Polski Bank Komórek Macierzystych sp. z o.o., Poland, (“PBKM”), a wholly owned subsidiary of FamiCord AG, has today entered into an agreement with Primecell Advanced Therapy, a.s., Czech Republic, (“Primecell”) to acquire a further 69% of the shares in Národní centrum pupečníkové krve s.r.o., Czech Republic, as well as a further 69% of the shares in Rodinná banka perinatálnych a mezenchymálnych buniek s.r.o., Slovakia. 

PBKM thereby increases its stake in Národní centrum pupečníkové krve s.r.o. and respectively in Rodinná banka perinatálnych a mezenchymálnych buniek s.r.o. from 26% to 95%. With a 5% shareholding, Primecell will remain a shareholder and strategic partner of Národní centrum pupečníkové krve s.r.o. and Rodinná banka perinatálnych a mezenchymálnych buniek s.r.o. PBKM has an option to acquire these remaining 5% of shares as well for a pre-agreed fixed price. 

Národní centrum pupečníkové krve s.r.o. and Rodinná banka perinatálnych a mezenchymálnych buniek s.r.o. are family stem cell banks focused on collection, testing, processing and storage of cord blood and cord tissue of newborns. Národní centrum pupečníkové krve s.r.o. operates a stem cell processing laboratory located in bioincubator 4MEDi, Ostrava, Czech Republic. Both companies offer services similar to other companies of FamiCord Group. 

The agreed purchase price for the shares is equivalent to a mid single-digit million Euro amount, payable in cash. In addition, PBKM and Primecell are discussing potential cooperation in the area of promoting and developing cell-based therapies in Europe which might include sharing know-how and the transfer of certain intellectual property. The parties agreed to separately transfer certain Národní centrum pupečníkové krve s.r.o. patent to PBKM. 

FamiCord Group and Primecell intend to cooperate to preserve cells for personalized health enhancing therapies. Further, both parties intend to cooperate in cell-based research, regenerative medicine applications and to share expertise of their R&D teams.

The transaction is expected to close in June 2025. The Management Board is currently reviewing the potential impact of the acquisition on the forecast of FamiCord AG for the 2025 financial year.

Notifying Person: Jakub Baran, CEO